CPC Scientific Corporate Video
Marketing Team
CPC Scientific Inc.
Who We Are and What We Do.
Founded in 2001, we are the third largest peptide-focused contract research, development, and manufacturing organization (“CRDMO”) worldwide in the of terms of sales revenue in 2023, according to Frost & Sullivan. We are also considered one of the most comprehensive peptide-focused CRDMO globally (Frost & Sullivan), offering complete life-cycle support from early-discovery, pre-clinical research and clinical development to commercial production.
We provide (i) contract research organization (“CRO”) services, including peptide new chemical entity (“NCE”) discovery synthesis; (ii) contract development and manufacturing organization (“CDMO”) services, including peptide chemistry, manufacturing, and controls (“CMC”) development; and (iii) contract manufacturing organization (“CMO”) services, including peptide NCE and generic drug commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets in the United States, China, Japan, Europe, South Korea, and Australia. We also provide customers wit peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide.
We are a full-service peptide-focused CRDMO with vertically integrated capabilities in peptide drug development and manufacturing. Given the increasing complexity of new peptide drugs, which makes the development and manufacturing of peptides a time- and capital-intensive process, our tailored services are ideally suited for pharmaceutical and biotechnology companies seeking outsourcing solutions for their development and manufacturing needs.
Best Regards,
CPC Scientific Inc.
Rocklin Facility Construction Update: Advancing U.S.-Based Peptide API Manufacturing
Rocklin Facility Construction Update: Advancing U.S.-Based Peptide API Manufacturing
CPC Scientific’s Rocklin facility is undergoing a major expansion to establish a 41,000 sq ft Center of Excellence for U.S.-based peptide API manufacturing. Construction is now underway—more updates coming soon.
Medtide Inc., CPC Scientific’s Parent Company, Debuts on Hong Kong Stock Exchange
Medtide Inc., CPC Scientific’s Parent Company, Debuts on Hong Kong Stock Exchange
Join us as we celebrate a proud milestone: the successful listing of Medtide Inc., parent company of CPC Scientific, on the main board of the Hong Kong Stock Exchange in June 2025. This moment marks a new chapter of growth, innovation, and global impact for our organization.
Green Approaches to Peptide & Peptide–Oligo Conjugate Manufacturing
Green Approaches to Peptide & Peptide–Oligo Conjugate Manufacturing
Sheri Ambriz, MBA took the stage at TIDES USA 2025 in San Diego, CA, to share insights on green approaches to peptide and peptide–oligonucleotide conjugate manufacturing.
